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RNA Polymerase IIThe human CCCTC-binding factor, CTCF, regulates transcription of the double-stranded DNA genomes of
herpesviruses. The architectural complex cohesin and RNA Polymerase II also contribute to this organization.
We proﬁled the occupancy of CTCF, cohesin, and RNA Polymerase II on the episomal genome of the Epstein–
Barr virus in a cell culture model of latent infection. CTCF colocalizes with cohesin but not RNA Polymerase II.
CTCF and cohesin bind speciﬁc sequences throughout the genome that are found not just proximal to the
regulatory elements of latent genes, but also near lytic genes. In addition to tracking with known transcripts,
RNA Polymerase II appears at two unannotated positions, one of which lies within the latent origin of
replication. The widespread occupancy proﬁle of each protein reveals binding near or at a myriad of
regulatory elements and suggests context-dependent functions.a).
-NC-ND license.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The human CCCTC-binding factor, CTCF, regulates gene expression
by organizing DNA in the three-dimensional space of the nucleus.
CTCF binds tens of thousands of sites throughout the human genome
(Barski et al., 2007; Kim et al., 2007) and is necessary for the assembly
of chromatin loops that bring together distal DNA to regulate
transcription (Hou et al., 2010; Majumder and Boss, 2010; Majumder
et al., 2008; Mishiro et al., 2009). Globally, the human genome is
organized by long-range interactions (Lieberman-Aiden et al., 2009)
and binding sites are signiﬁcantly enriched at these nodes (Botta et al.,
2010). CTCF also organizes the double-stranded DNA genomes of
herpesviruses. Binding sites have been identiﬁed on the Epstein–Barr
virus (EBV) (Chau et al., 2006; Day et al., 2007; Tempera et al., 2010),
herpes simplex virus 1 (Chen et al., 2007), and Kaposi's sarcoma-
associated herpesvirus (KSHV) (Stedman et al., 2008). Functional
studies with EBV have focused on binding sites near the major
promoters of latency and suggested possible roles for CTCF in the
repression, activation, and insulation of latent transcripts (Chau et al.,
2006; Day et al., 2007; Tempera et al., 2010). CTCF occupancy
upstream of the C promoter arguably correlates with repression of
EBNA2 transcription (Chau et al., 2006; Salamon et al., 2009).
Mutation of a CTCF-binding site upstream of the Q promoter resulted
in loss of EBNA1 transcription accompanied by the spread ofrepressive histone marks and CpG methylation (Tempera et al.,
2010). Based on a myriad of functions, CTCF has emerged as a central
component of transcriptional regulation in human and viral genomes.
CTCF may form complexes with diverse binding partners that
include transcription factors, histone modiﬁers, and a variety of
chromatin regulators (Wallace and Felsenfeld, 2007; Zlatanova and
Caiafa, 2009). The CTCF protein consists of eleven zincﬁngers (Filippova
et al., 1996) and two ﬂanking unstructured termini (Martinez and
Miranda, 2010); both types of protein segments are capable of recruiting
cofactors directly by molecular recognition (Dunker et al., 2002;
Gamsjaeger et al., 2007). Speciﬁcally, the architectural complex cohesin
and RNA Polymerase II (RNAP II) may play functional roles in CTCF-
dependent transcriptional control. CTCF is necessary for cohesin
positioning and colocalization throughout the human, mouse, and
KSHV genomes (Parelho et al., 2008; Stedman et al., 2008;Wendt et al.,
2008). Depletion of cohesin perturbs gene expression by the disruption
of DNA looping and long-range interactions between transcriptional
control elements (Hadjur et al., 2009; Mishiro et al., 2009; Nativio et al.,
2009).RNAP II is thought to interactwithCTCFdirectly throughprotein–
protein interactions, resulting in colocalization at a subset of CTCF-
binding sites (Chernukhin et al., 2007). Stalling of RNAP II tends to occur
at sites of CTCF and cohesin colocalization (Wada et al., 2009), and a
large fraction of CTCF sites are found within actively transcribed genes
(Barski et al., 2007). The diversity and genome-wide distribution of the
myriad of possible CTCF assemblies, given signiﬁcant functional
implications, remains actively investigated.
We initially hoped to use proﬁling of protein occupancy to
determine the composition of CTCF complexes by identifying which
proteins bind the same DNA at high resolution. Colocalization would
2 Rapid Communicationstrongly suggest molecular assembly and cooperation, perhaps
characterizing the structural and functional heterogeneity or unifor-
mity of complexes genome-wide. Indeed, we were able to do so and
determined that CTCF colocalizes with cohesin but not RNAP II. In the
midst of identifying binding sites, however, we also uncovered
protein occupancy in unexpected regions of the EBV genome. We
will discuss the functional implications of CTCF and cohesin
colocalization as well as RNAP II binding outside regions of known
transcription.
Results
CTCF and cohesin colocalization
CTCF binds speciﬁc sites throughout the latent EBV genome. We
identiﬁed ﬁfteen sites of CTCF occupancy at high resolution across theFig. 1. Occupancy of CTCF, cohesin, and RNA Polymerase II in the Epstein–Barr virus genome.
and (C) the RPB1 subunit of RNA Polymerase II in the latent Epstein–Barr virus genome of Raj
as enrichment over the background baseline.entire unique sequence of the EBV genome using chromatin
immunoprecipitation followed by deep sequencing (ChIP-seq)
(Fig. 1, Table 1). An overrepresented sequence motif, similar to that
found in the human genome (Kim et al., 2007), is detected in every
region of occupancy (data not shown). During the life cycle of EBV,
only a handful of regulatory elements control expression of a few
latent genes, but many more genes are transcribed upon lytic
activation (Kieff and Rickinson, 2007). We ﬁnd CTCF-binding sites
proximal to many latent regulatory elements. Occupancy is observed
near the C, W, and Q promoters that drive messages encoding for the
EBNA proteins. Enrichment is also detected close to start sites of the
EBER-1 non-coding RNA and RPSM1 BART transcript, as well as the
LMP-2A and LMP-1 messages. We also ﬁnd, however, CTCF-binding
sites proximal tomany lytic genes. For example, occupancy is detected
near the promoter of BZLF1, an immediate early transactivator critical
for the switch to the productive cycle (Biggin et al., 1987). BothChromatin immunoprecipitation proﬁles of (A) CTCF, (B) the RAD21 subunit of cohesin,
i cells. The proﬁle of (D) input DNA serves as a control reference. Occupancy is calculated
Table 1
CTCF and cohesin occupancy of the Raji EBV genome.
CTCF-binding
sites
RAD21-binding
sites
Nearby transcriptional regulatory
elementa
6411–6580 EBER-1 (pol III transcript) [misc RNA]
10483–10633 C promoter (Cp) used in latency III
[TATA signal]
35899–36054 35902–36081 EBNA-LP, W promoter (Wp) used in
earlier stages of latent infection
[TATA signal]
50019–50166 50010–50164 EBNA-1, QUK transcript, starts from
the Q promoter (Qp) in latency I [mRNA]
63435–63584 BOLF1 [TATA signal]
67872–68022 67892–68041 BMRF1 [TATA signal]
75554–75705 BLRF1 [TATA signal]
91180–91331 91189–91339 BZLF1 [TATA signal]
116241–116386 116213–116378 BGLF1 [TATA signal]
122920–123090 BDLF1 [TATA signal]
133362–133528 BVRF1 [TATA signal]
138827–139018 RPMS1, BART mRNAs [mRNA]
145778–145959 LF3 [TATA signal]
166435–166588 166416–166570 LMP-2A [TATA signal]
168369–168541 LMP-1 [TATA signal]
a From the human herpesvirus 4 complete genome sequence (Genbank ID:
NC_007605.1).
3Rapid Communicationtranscripts expressed during latency as well as genes activated during
the lytic cycle can be found proximal to CTCF-binding sites.
Cohesin colocalizes with CTCF throughout the latent EBV genome.
We measured the occupancy of the kleisin subunit RAD21 and
identiﬁed six binding sites for cohesin dispersed throughout the EBV
genome (Fig. 1, Table 1). All of these cohesin-binding sites overlap
with CTCF-binding sites at high resolution; no CTCF-independent sites
of cohesin occupancy are found. We did not detect RAD21 enrichment
at all sites of CTCF occupancy, presumably due to weaker efﬁciency of
immunoprecipitation with the RAD21 antibody compared to the CTCF
antibody. Similar to the distribution of CTCF-binding sites, the
overlapping cohesin-binding sites are found proximal to regulatory
elements of both latent and lytic genes.
RNA Polymerase II occupancy
RNAP II does not colocalize with CTCF, but instead tracks with
regions of known transcription and appears highly enriched at
unannotated positions. We measured RNAP II occupancy and
identiﬁed four signiﬁcant regions of binding (Fig. 1, Table 2). The
particular antibody used in our experiments, 4H8, was raised against
an epitope containing phosphorylated serine 5 and therefore detects
occupancy both at promoters and throughout a transcribed gene
(Brodsky et al., 2005; Stock et al., 2007). Binding is observed at ~6.5–
6.9 and ~6.9–7.1 kbp, regions corresponding to the two EBER
transcripts that span ~6.6–6.8 and ~7.0–7.1 kbp (Rosa et al., 1981).
The observed peaks are distributed across the entire gene, a pattern
consistent with actively elongating transcription. Although the signals
did not rise above our signiﬁcance threshold, we also detected some
RNAP II enrichment near other known transcription units. Occupancy
at ~138.3–138.5 kbp corresponds to the initiation site of the RPSM1Table 2
RNA Polymerase II occupancy of the Raji EBV genome.
RPB1-binding sites Nearby transcriptional regulatory elementa
5878–6042 EBER-1 (pol III transcript) [misc RNA]
6549–6865 EBER-1 (pol III transcript) [misc RNA]
6895–7142 EBER-2 (pol III transcript) [misc RNA]
8146–8295 region containing oriP, the latent cycle origin of
DNA replication [rep origin]
a From the human herpesvirus 4 complete genome sequence (Genbank ID:
NC_007605.1).BART transcript, and the binding at ~169.1–169.3 kbp occurs near the
promoters of the LMP genes (Fig. 1). In addition to sites of active
transcription, we observed the strongest levels of enrichment at two
novel positions (Fig. 1, Table 2). Recruitment occurs ~1 kbp upstream
of the EBER-1 transcript at ~5.9–6.0 kbp. Occupancy is also strong at
~8.1–8.3 kbp, inside oriP, the proposed latent cycle origin of
replication (Yates et al., 1984), at a unique sequence adjacent to FR,
repeats that function in replication (Reisman et al., 1985) and
transcriptional activation (Gahn and Sugden, 1995; Reisman and
Sugden, 1986). Although we detected multiple RNAP II-binding sites,
both at known transcription units and unannotated positions, none of
these sites colocalized with CTCF.Discussion
High-resolution mapping of protein positions with ChIP-seq on
small viral episomes yields advantages over similar experiments in
larger genomes: technical gains allow conﬁdent data analysis and
veriﬁed annotations help generate functional hypotheses of protein
function. The high copy number of episomes, ~45 in the case of EBV-
infected Raji cells (Sternas et al., 1990), increases the signal-to-noise
ratio of ChIP experiments because of deeper sequencing compared to
the simultaneously examined human genome. Multifold coverage of
the background consequently allowed us to statistically deﬁne an
experimental baseline for experiments. This simpliﬁed peak calling to
choosing a suitable enrichment over background; our conservative
threshold of a 10-fold enrichment yielded an ostensible false
discovery rate of 0 and strong conﬁdence in our identiﬁcation of
binding sites. Viral genomes have also been well annotated and
subjected to functional mutagenesis experiments. Once protein-
binding sites have been determined at high resolution, we can
correlate occupancywith known and tested sequence elements. These
advantages yield reliable distributions of occupancy that allow us to
make functional inferences based on protein positions.
Widespread distribution of CTCF and cohesin on the EBV genome
reveals binding at or near both latent and lytic genes, suggesting
distinct regulatory functions at different positions. Focus on CTCF
function in EBV has been limited to binding sites within the latency
control region, and consequently potential roles for CTCF have only
involved the determination of latent promoter choice and establish-
ment of boundaries between latent and lytic genes (Chau et al., 2006;
Day et al., 2007; Tempera et al., 2010). Our experiments identiﬁed
CTCF-binding sites widely dispersed on the genome, including in and
around many lytic genes. We also observed colocalization with
cohesin, similar to what is observed in the human and KSHV genomes
(Parelho et al., 2008; Stedman et al., 2008; Wendt et al., 2008), that is
likewise not limited to areas of latent transcription initiation. Because
of the widespread occupancy distributions, we surmise that CTCF and
cohesin may be performing functions near lytic genes separate from
those previously suggested in latency control regions.
RNAP II does not colocalize with CTCF, and RNAP II positioning
suggests functions separate from the transcription of latent genes. We
ﬁnd RNAP II at the EBER transcripts, short non-coding RNA with
expression predominantly driven by RNA Polymerase III but also
partially transcribed by RNAP II (Kirchner et al., 1991). We also ﬁnd
RNAP II at two novel positions, sites that yield the strongest
enrichment of occupancy in our experiments yet do not map to any
annotated transcripts. The strongest signal maps to the unique
sequence adjacent to FRwithinOriP, the proposed origin of replication
for latency. The second strongest RNAP II signal maps upstream of the
EBER-1 transcript and does not appear to correspond to an annotated
element. We were unable, however, to ﬁnd CTCF occupancy at any of
these RNAP II-binding sites. We also could not detect RNAP II and
cohesin colocalization as observed in the human genome (Kagey et al.,
2010). RNAP II, like CTCF and cohesin, binds near different regulatory
4 Rapid Communicationelements throughout the genome, thus suggesting functions ranging
from transcription to replication.
RNAP II occupancy detects a subset of known transcription units in
the EBV-infected Raji cells, but CTCF proximity correlates with both
active and repressed promoters. The two EBER RNAs are actively
transcribed (Lerner et al., 1981) and strong RNAP II enrichment is
observed. A complex set of alternatively spliced mRNAs, referred to as
BARTs, are generated from the rightward transcription of the BamHI A
fragment (Chen et al., 1992; Sadler and Raab-Traub, 1995). Different
initiation sites have been proposed, but we detect a weak signal in only
one promoter (Smith et al., 1993). Similarly, conﬂicting evidence exists
regarding the identity of the transcription start site (Tao et al., 1998;
Woisetschlaeger et al., 1990) for the set of alternatively spliced mRNAs
that yield the EBNA genes (Allday et al., 1988; Petti et al., 1988; Wang
et al., 1987). Although theWpromoter is obscured from our analysis by
repeat regions, we ﬁnd RNAP II at neither the C nor Q promoters. This
cell line also expresses the LMP1 gene (Contreras-Brodin et al., 1991), as
well as LMP2A but not LMP2B (Sample et al., 1989). Although weak
RNAP II enrichment is observed in the general promoter region for these
messages, the peak does not correlate to an annotated element.
Combining our RNAP II localization with literature describing known
transcription in Raji cells gives us the opportunity to compare CTCF
occupancy with polymerase distribution. Again, however, neither
activity nor putative repression of promoters correlates with CTCF
proximity.We interpret CTCF occupancy near both active and repressed
promoters as another suggestion of context-dependent gene regulation.
Combining conﬁdent, high resolution mapping of protein positions
byChIP-seq and thedeep annotation of viral genomes allows us tomake
speciﬁc and testable inferences.What functions can we hypothesize for
CTCF, cohesion, and RNAP II? In addition to operatingwithin the latency
control region, CTCF and cohesin colocalization near lytic genes may
control those regulatory elements, for example by repressing lytic
transcription. In addition to generating latent transcripts, occupancy at
the origin may couple RNAP II recruitment with replication. CTCF,
cohesin, and RNAP II all share the common potential of context-
dependent functions throughout the EBV genome.
Materials and methods
Cell culture and antibodies
EBV genome-positive Raji cells (Pulvertaft, 1964) (ATCC CCL-86)
were maintained in RPMI-1640 media containing 25 mM HEPES and
supplemented with 10% (v/v) fetal bovine serum and 0.01% (v/v)
β-mercaptoethanol. Antibodies used were anti-CTCF (Millipore, 07-
729), anti-Rad21 (Bethyl Labs, A300-080A), and 4H8 (Abcam, ab5408).
Chromatin immunoprecipitation followed by deep sequencing
1×107 Raji cells were used per ChIP-seq experiment. Crosslinking
was performed by adding formaldehyde to 1% (v/v) at room
temperature for 3, 10, and 5 min for CTCF, Rad21, and RNAP II
immunoprecipitations, respectively. The reaction was quenched by
adding glycine to 125 mM for 10 min at 4 °C. Cells were pelleted at
1000 g for 5 min at room temperature and resuspended in 50 mM
HEPES-KOH, 1 mM EDTA, 150 mMNaCl, 10% (v/v) glycerol, 0.5% (v/v)
Triton X-100, Complete Protease Inhibitor Cocktail Tablets (Roche),
pH 7.4, for 30 min at 4 °C. Crude nuclei were collected by
centrifugation at 600 g for 5 min and lysed in 10 mM Tris­HCl, 1 mM
EDTA, 150 mM NaCl, 5% (v/v) glycerol, 0.1% (w/v) sodium deoxycho-
late, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, Complete Protease
Inhibitor Cocktail Tablets (Roche), pH 8.0. DNA was sheared with a
Bioruptor water bath sonicator (Diagenode) to produce fragments
~100–200 bp in size. A fraction of the sample was set aside as a
genomic DNA input control and crosslinking was reversed in 10 mM
Tris, 1 mM EDTA, 0.7% (w/v) SDS, 200 μg/mL proteinase K, pH 8.0, at55 °C for 3 h followed by incubation at 65 °C overnight. DNA–protein
complexes were puriﬁed using 10 μg epitope-speciﬁc antibodies and
100 μl protein G Dynabeads (Invitrogen) for 4 h at 4 °C and followed
by consecutive washes, ﬁrst in 10 mM Tris–HCl, 1 mM EDTA, 150 mM
NaCl, 5% (v/v) glycerol, 0.1% (w/v) sodium deoxycholate, 0.1% (w/v)
SDS, 1% (v/v) Triton X-100, Complete Protease Inhibitor Cocktail
Tablets (Roche), pH 8.0, second in the same buffer with 500 mMNaCl,
and last in 20 mM Tris–HCl, 1 mM EDTA, 250 mM LiCl, 0.5% (v/v) NP-
40, 0.5% (w/v) sodium deoxycholate, Complete Protease Inhibitor
Cocktail Tablets (Roche), pH 8.0. Complexes were eluted from the
beads with 10 mM Tris, 1 mM EDTA, 0.7% (w/v) SDS, pH 8.0, and
crosslinking was reversed as with the input control DNA.
ChIP-seq librarieswere prepared by adaptor-mediated ampliﬁcation
(Robertson et al., 2007) with a few modiﬁcations. Both ChIP DNA and
10 ng of input DNA were repaired and phosphorylated with T4 DNA
Polymerase, KlenowPolymerase, and T4PolynucleotideKinase. Double-
stranded oligonucleotides based on genomic adapters (Illumina) were
synthesized such that the product corresponded to the two adapters
joined together at blunt ends and separated by deoxyuridine. After the
addition of a 3′ adenine to the repaired DNA, samples were ligated
overnight to the modiﬁed adapters in a 2:1 adapter:sample ratio.
Ligation reactionsweredigestedwithuracil-DNAglycosylase for 30 min
at 37 °C. Ampliﬁcation of the DNA libraries was performed using PCR
primers 1.1 and 1.2 (Illumina) for 18 cycles. The resulting PCR products
were puriﬁed using Ampure beads (Agencourt). Size fractionation and
purity of the ﬁnished ChIP-seq DNA libraries were monitored with a
DNA 1000 Assay (Agilent). DNA concentrations were quantiﬁed using a
combination of Quant-iT PicoGreen (Invitrogen) and UV absorbance to
obtain a diluted ﬁnal concentration of 10 nM. Clusters were generated
on a Cluster Station (Illumina) and 36 cycles of sequencing performed
with a Genome Analyzer II (Illumina). All ChIP-seq experiments were
performed with independent replicates.
Sequence mapping and analysis
After ignoring the ﬁrst basecall, 32 bp sequence fragments were
obtained and mapped to the EBV reference genome (Genbank ID:
NC_007605.1) using the Pipeline software (Illumina) allowing for up to
2 mismatches. Unique sequence tags were extracted and merged for
each duplicate experiment. For the input, CTCF, cohesin, and RNAP II
experiments, the combined data sets consisted of 3,164 plus 1,674,
11,937 plus 41,829, 4,474 plus 13,965, and 11,336 plus 7,292 sequences,
respectively. Data was further processed with scripts written in AWK.
Corresponding to the original DNA fragment size loaded onto the
sequencer, the 32 bp tags were extended directionally by 100 bp and
the number of hits per genomeposition counted. Each data setwas then
normalized to the internal baseline. Hits corresponding to deleted and
repeat regions of the genome were ﬁrst masked. The unmasked values
were then sorted by count number and the mean and median values
calculated. This set was culled in 1% increments, removing the highest
values, until the calculated mean equaled less than the median. This
process simulates removal of peaks from a data set until only a
background remains. The last calculated mean is thus equivalent to the
average number of hits within the background. All sequence hit counts
were thendividedby this value. This normalization results in expression
of the reported peak heights relative to background. The selection
criteria used for identifying abindingsitewere that eachpeakcontain an
approximately equal proportion of forward and reverse reads and that
the maximum of each peak has a minimum ten-fold enrichment over
background in both replicate experiments. Peak coordinates are
expressed as the full width at half maximum height.
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